Physician profile
Saroj Sehgal
NPI 1871512616
$785.13
in general payments reported to CMS, 2019-2025
16 companies · $83.24 in 2025
The $83.24 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.01 · 2021: $14.93 · 2022: $125 · 2023: $58.47 · 2024: $489 · 2025: $83.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $581 · Education: $50.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $580.74 |
| Education | $50.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $315.67 | 2022-2025 | Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $148.56 | 2024 | Arexvy, Trelegy Ellipta |
| Opko Pharmaceuticals, LLC | $50.46 | 2023-2024 | Rayaldee |
| Amgen INC. | $33.54 | 2024 | Krystexxa |
| Gilead Sciences, INC. | $28.45 | 2021-2023 | Veklury |
| Otsuka America Pharmaceutical, INC. | $28.13 | 2023 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $25.38 | 2024 | |
| Renalytix Ai, INC. | $22.73 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Lilly USA, LLC | $17.84 | 2025 | Kisunla |
| Phadia US INC. | $17.61 | 2024 | Immunocap |
| Calliditas Therapeutics US INC. | $17.48 | 2024 | |
| Mallinckrodt Hospital Products INC. | $17.17 | 2024 | Acthar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.51 | 2025 | Caplyta |
| Neurocrine Biosciences, INC. | $16.03 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $15.56 | 2025 | Austedo Xr |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $14.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saroj Sehgal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.